Aurinia Pharmaceuticals Inc.
AUPHNasdaq
$15.96
↑ +0.1%Jul 17 close · end-of-day
Price
1Y↑ +80.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.2B
Enterprise Value
$2.2B
P/E
7.4
P/S
7.4
P/B
3.9
EV/EBITDA
15.0
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$298.3M
Net Income (TTM)
$298.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
41.7%
Net Margin
100.0%
ROE
52.5%
ROIC
23.6%
Debt / Equity
—
Net Cash
$40.7M
Return 1Y
+76.0%
Company profile
Aurinia Pharmaceuticals Inc. focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
- CEO
- Peter S. Greenleaf
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 300
- Headquarters
- Alberta
- Website
- auriniapharma.com
Management & directors
- Tang Kevin CChief Executive Officer
- Cole RyanChief Operating Officer
- Hearne Michael SChief Financial Officer
- Robertson Stephen P.EVP, General Counsel
- Keenan GregSVP, Chief Medical Officer
- Donley Matthew MaxwellChief Operating Officer
- Greenleaf PeterChief Executive Officer
- Miller Joseph MChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
AUPH Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$77.7M↑ +24.4%
Diluted EPS$0.25↑ +56.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $50.1M | $45.6M | $134.0M | $175.5M | $235.1M | $283.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$104.3M | -$180.7M | -$111.5M | -$91.7M | -$4.7M | $104.9M |
| Net income | -$102.7M | -$181.0M | -$108.2M | -$78.0M | $5.8M | $287.2M |
| Diluted EPS | -$0.87 | -$1.40 | -$0.76 | -$0.54 | $0.04 | $2.07 |
| Operating cash flow | -$69.9M | -$157.7M | -$79.5M | -$33.5M | $44.4M | $135.7M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -208.1% | -396.3% | -83.2% | -52.2% | -2.0% | 37.1% |
| Net margin | -204.9% | -396.9% | -80.7% | -44.4% | 2.5% | 101.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $57.2M | $67.8M | $59.9M | $62.5M | $70.0M | $73.5M | $77.1M | $77.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.5M | $11.7M | -$1.7M | $21.8M | $20.1M | $29.7M | $33.2M | $41.4M |
| Net income | $722,000.00 | $14.3M | $1.4M | $23.3M | $21.5M | $31.6M | $210.8M | $34.4M |
| Diluted EPS | $0.01 | $0.10 | $0.01 | $0.16 | $0.16 | $0.23 | $1.53 | $0.25 |
| Operating cash flow | $15.8M | $17.0M | $30.1M | $1.3M | $44.2M | $44.4M | $45.7M | $32.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -2.6% | 17.3% | -2.8% | 35.0% | 28.7% | 40.5% | 43.1% | 53.3% |
| Net margin | 1.3% | 21.2% | 2.4% | 37.4% | 30.7% | 42.9% | 273.4% | 44.2% |
Company news
Jun 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-02 | TANG KEVIN C· Chief Executive Officer | Buy | 206,005 | $15.28 | $3.1M | filing |
| 2026-06-01 | TANG KEVIN C· Chief Executive Officer | Buy | 343,521 | $15.28 | $5.2M | filing |
| 2026-06-01 | TANG KEVIN C· Chief Executive Officer | Buy | 99 | $15.34 | $1,518.66 | filing |
| 2026-05-29 | TANG KEVIN C· Chief Executive Officer | Buy | 262,682 | $15.31 | $4.0M | filing |
| 2026-05-29 | TANG KEVIN C· Chief Executive Officer | Buy | 2,299 | $15.35 | $35,289.65 | filing |
| 2026-05-18 | Robertson Stephen P.· Chief Legal Officer | Award | 115,541 | $0.00 | $0.00 | filing |
| 2026-05-18 | Hearne Michael S· Chief Financial Officer | Award | 116,144 | $0.00 | $0.00 | filing |
| 2026-05-18 | Cole Ryan· Chief Operating Officer | Award | 116,144 | $0.00 | $0.00 | filing |
| 2026-03-06 | Keenan Greg· SVP, Chief Medical Officer | Tax withholding | 8,069 | $14.32 | $115,548.08 | filing |
| 2026-03-03 | TANG KEVIN C | Buy | 184,208 | $14.22 | $2.6M | filing |
| 2026-03-02 | TANG KEVIN C | Buy | 115,792 | $14.21 | $1.6M | filing |
| 2026-03-02 | Greenleaf Peter· Chief Executive Officer | Tax withholding | 100,890 | $14.21 | $1.4M | filing |
| 2026-03-02 | TANG KEVIN C | Buy | 83,561 | $14.33 | $1.2M | filing |
| 2026-03-02 | Donley Matthew Maxwell· Chief Operating Officer | Tax withholding | 40,761 | $14.21 | $579,213.81 | filing |
| 2026-03-02 | Miller Joseph M· Chief Financial Officer | Tax withholding | 37,511 | $14.21 | $533,031.31 | filing |
| 2026-03-02 | Robertson Stephen P.· EVP, General Counsel | Tax withholding | 36,525 | $14.21 | $519,020.25 | filing |
| 2026-02-27 | TANG KEVIN C | Buy | 300,000 | $13.90 | $4.2M | filing |
| 2026-02-27 | TANG KEVIN C | Buy | 214,839 | $14.12 | $3.0M | filing |
| 2026-02-27 | TANG KEVIN C | Buy | 1,600 | $14.38 | $23,008.00 | filing |
| 2026-02-27 | Donley Matthew Maxwell· Chief Operating Officer | Award | 58,160 | $0.00 | $0.00 | filing |
| 2026-02-27 | Miller Joseph M· Chief Financial Officer | Award | 57,229 | $0.00 | $0.00 | filing |
| 2026-02-27 | Greenleaf Peter· Chief Executive Officer | Award | 196,403 | $0.00 | $0.00 | filing |
| 2026-02-27 | Keenan Greg· SVP, Chief Medical Officer | Award | 40,586 | $0.00 | $0.00 | filing |
| 2026-02-27 | Robertson Stephen P.· EVP, General Counsel | Award | 59,090 | $0.00 | $0.00 | filing |
| 2026-02-20 | Greenleaf Peter· Chief Executive Officer | Tax withholding | 100,171 | $14.40 | $1.4M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.